Shionogi and NEC collaborate on hepatitis B vaccine
High unmet need in the area of hepatitis B therapies will see companies share responsibilities to develop the vaccine
Read More
Tag: hepatitis B
Gilead and Vir unite to find a ‘functional cure’ for hepatitis B
Companies will collaborate on a combination therapy study
Read More
Vemlidy tackles hep B in late-stage trials
The impact of chronic hepatitis B treatment on hepatocellular carcinoma incidence was evaluated in a long-term analysis of the Gilead drug.
Read More
Ionis to license hep B programme to GSK
GSK is now responsible for all development, regulatory and commercialisation activities and costs.
Read More
FDA clears first new hep B vaccine in 25 years
The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Read More
EU approves Gilead’s hepatitis B therapy Vemlidy
Patients with chronic hepatitis B in Europe have gained the first new treatment option in nearly 10 years following the approval of Gilead’s Vemlidy.
Read More
FDA rejects Dynavax’ hepatitis B vaccine
Shares in US group Dynavax Technologies fell through the floor after US regulators refused to approve its flagship hepatitis B vaccine Heplisav-B.
Read More
Roche pulls plug on Inovio deal
Roche has pulled the plug on its collaboration with Inovio after stepping away from the development of the second candidate, the hepatitis B DNA immunotherapy INO-1800.
Read More
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
